The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
B cell and B cell-related pathways for novel cancer treatments
Open accessAbstract
B cells are recognized as the main effector cells of humoral immunity which suppress tumor progression by secreting immunoglobulins, promoting T cell response, and killing cancer cells directly. Given these properties, their anti-tumor immune response in the tumor micro-environment (TME) is of great interest. Although T cell-related immune responses have become a therapeutic target with the introduction of immune checkpoint inhibitors, not all patients benefit from these treatments. B cell and B cell-related pathways (CCL19, -21/CCR7 axis and CXCL13/CXCR5 axis) play key roles in activating immune response through humoral immunity and local immune activation via tertiary lymphoid structure (TLS) formation. However they have some protumorigenic works in the TME. Thus, a better understanding of B cell and B cell-related pathways is necessary to develop effective cancer control. In this review, we summarize recent evidences regarding the roles of B cell and B cell-related pathways in the TME and immune response and discuss their potential roles for novel cancer treatment strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079
Self-citationT follicular helper cell differentiation, function, and roles in disease
Crotty, S. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.004 · Cited by 1,847
Morita, R., Schmitt, N., Bentebibel, S.-E., Ranganathan, R., Bourdery, L., Zurawski, G., Foucat, E., Dullaers, M., Oh, S., Sabzghabaei, N., et al. (2011) · Immunity · doi:10.1016/j.immuni.2010.12.012 · Cited by 1,563
CCR7 and its ligands: balancing immunity and tolerance
Förster, R., Davalos-Misslitz, A. C., & Rot, A. (2008) · Nature Reviews Immunology · doi:10.1038/nri2297 · Cited by 1,410 · cited 6×
“However, naive T cells expressing CCR7 mainly recognize CCL19 and CCL21 produced in T cell zone of SLOs, and migrate to T cell zone through HEVs [71] (Figure 2).”
BackgroundInfluentialFollicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions
Chung, Y., Tanaka, S., Chu, F., Nurieva, R. I., Martinez, G. J., Rawal, S., Wang, Y.-H., Lim, H., Reynolds, J. M., Zhou, X.-H., et al. (2011) · Nature Medicine · doi:10.1038/nm.2426 · Cited by 1,120
Palucka, A. K., & Coussens, L. M. (2016) · Cell · doi:10.1016/j.cell.2016.01.049 · Cited by 843
Germain, C., Gnjatic, S., Tamzalit, F., Knockaert, S., Remark, R., Goc, J., Lepelley, A., Becht, E., Katsahian, S., Bizouard, G., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201309-1611oc · Cited by 833
Le, D. T., Wang-Gillam, A., Picozzi, V., Greten, T. F., Crocenzi, T., Springett, G., Morse, M., Zeh, H., Cohen, D., Fine, R. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.4244 · Cited by 611
Th17 Cells Induce Ectopic Lymphoid Follicles in Central Nervous System Tissue Inflammation
Peters, A., Pitcher, L. A., Sullivan, J. M., Mitsdoerffer, M., Acton, S. E., Franz, B., Wucherpfennig, K., Turley, S., Carroll, M. C., Sobel, R. A., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.10.015 · Cited by 480 · cited 1×
“This study also clarified that this treatment suppressed the Treg pathway and enhanced Th17 pathway, in accordance with studies showing that Tregs can suppress TLS development [61], and that Th17 cells can promote TLS development [62].”
ResultThe Inhibitory Receptor PD-1 Regulates IgA Selection and Bacterial Composition in the Gut
Kawamoto, S., Tran, T. H., Maruya, M., Suzuki, K., Doi, Y., Tsutsui, Y., Kato, L. M., & Fagarasan, S. (2012) · Science · doi:10.1126/science.1217718 · Cited by 451 · cited 1×
“The immunosuppressive molecule PD-1 plays a role in controlling the activation of Tfh cells [36].”
BackgroundCXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer
Gu-Trantien, C., Migliori, E., Buisseret, L., de Wind, A., Brohée, S., Garaud, S., Noël, G., Dang Chi, V. L., Lodewyckx, J.-N., Naveaux, C., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.91487 · Cited by 368
Barnett, L. G., Simkins, H. M. A., Barnett, B. E., Korn, L. L., Johnson, A. L., Wherry, E. J., Wu, G. F., & Laufer, T. M. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301284 · Cited by 123 · cited 1×
“DCs make the antigen presentation to naive T cells, which promote differentiation from naive T cells into T follicular helper cells (Tfh cells) [14].”
Background
Cited by
CXCL13 and Its Receptor CXCR5 in Cancer: Inflammation, Immune Response, and Beyond
Kazanietz, M. G., Durando, M., & Cooke, M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00471 · Cited by 356
Ye, L., Zhao, G., Ma, J., Gan, Q., Luo, N., Pan, D., Chen, C., Chen, X., & Ning, S. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02769-3 · Cited by 10
“25 The developmental trajectory of nanovaccines has progressed through three evolutionary phases: (1) fi rst-generation lipid nanoparticles (LNPs) focused on stabilizing antigens and enhancing DC uptake, exempli fi ed by the COVID-19 mRNA vaccine platform, 26 (2) second-generation stimuli-responsive…”
Metadata
- Authors
- Tokunaga, R., Naseem, M., Lo, J. H., Battaglin, F., Soni, S., Puccini, A., Berger, M. D., Zhang, W., Baba, H., & Lenz, H.-J.
- Venue
- Cancer Treatment Reviews
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 73
- Pages
- 10-19
- ISSN
- 0305-7372 (ISSN-L)
- OpenAlex
- W2902244724
- Cited by
- 247
- References
- 12
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.